Evaluation of Chlorhexidine and Ethanol for Pre-Cannulation Antisepsis in Hemodialysis: A Randomized Crossover Trial

The primary objective of this study is to evaluate the efficacy of **chlorhexidine** compared to **ethanol** as antiseptic agents prior to cannulation in patients undergoing **hemodialysis**. This is clinically relevant as it aims to determine the most effective antiseptic in reducing infection rates, which is a critical concern in the management of patients receiving hemodialysis. The study is designed as a randomized crossover trial to ensure robust comparison between the two antiseptic agents.

The clinical trial involves participants diagnosed with **hemodialysis**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria for the trial population, as well as any specific lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Key inclusion or exclusion criteria are also not specified by the sponsor.

The clinical trial is designed as a **randomized crossover trial** to evaluate the effectiveness of **Chlorhexidine** and **Ethanol** in skin disinfection prior to cannulation for **hemodialysis**. The trial is set to commence recruitment on November 1, 2023, and is expected to conclude by May 31, 2024. Participants will be randomly assigned to receive either Chlorhexidine or Ethanol for skin disinfection in a crossover manner, ensuring each participant receives both treatments at different times during the study. This design allows for direct comparison within the same individual, minimizing variability and enhancing the reliability of the results.

The trial will include several study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will undergo a series of treatment visits where the assigned disinfection method will be applied prior to each **hemodialysis** session. These visits will be scheduled according to the participant's regular dialysis schedule. The end-of-study visit will occur after the completion of all treatment sessions, where final assessments will be conducted to evaluate the primary and secondary endpoints of the trial.

Participant involvement is expected to last for the duration of the trial, from the initial screening through to the end-of-study visit. However, conditions such as adverse reactions to the disinfection agents, non-compliance with study procedures, or withdrawal of consent may lead to early termination from the study. The trial aims to provide robust data on the comparative effectiveness of Chlorhexidine and Ethanol, contributing valuable insights into optimal disinfection practices for patients undergoing **hemodialysis**.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments such as standard-of-care therapy, placebo, or comparator treatment is not available. Additionally, details about drug administration, dosing schedules, and participant compliance monitoring are not included in the source data. As such, no further information can be offered regarding the substances used in this study.

The clinical trial is scheduled to commence recruitment on November 1, 2023, with an estimated completion date of May 31, 2024. The trial is categorized under phase 6, indicating a specific stage in the clinical research process. The efficacy of the intervention will be assessed through predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will adhere to a structured timeline to ensure systematic data collection and analysis. The study's design and execution will follow rigorous scientific standards to evaluate the intervention's impact accurately.